Denosumab
Denosumab | |
---|---|
Term | Denosumab |
Short definition | denosumab - (pronounced) (deh-noh-SOO-mab) drug used to prevent or treat certain bone problems. Denosumab is used under the brand name Xgeva to prevent bone problems caused by multiple myeloma or by solid tumors that have spread to the bone. |
Type | Cancer terms |
Specialty | Oncology |
Language | English |
Source | NCI |
Comments |
denosumab - (pronounced) (deh-noh-SOO-mab) drug used to prevent or treat certain bone problems. Denosumab is used under the brand name Xgeva to prevent bone problems caused by multiple myeloma or by solid tumors that have spread to the bone. It is also used in certain patients to treat giant cell tumors of the bone that cannot be surgically removed and to treat hypercalcaemia related to cancer that has not improved after treatment with bisphosphonates. Denosumab is also used under the brand name Prolia to increase bone mass in certain patients with breast cancer or prostate cancer who are at high risk of fractures. It is also used to treat osteoporosis in certain patients who are at high risk of breaking bones. Denosumab is also being studied to treat other diseases and cancers. It attaches to a protein called RANKL, which prevents RANKL from attaching to another protein called RANK on the surface of certain bone cells, including bone cancer cells. This can help prevent bone loss and cancer cell growth. Denosumab can also prevent calcium loss from the bones. It's a type of monoclonal antibody. Also called AMG 162
External links
- Medical encyclopedia article on Denosumab
- Wikipedia's article - Denosumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski